Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Sells $289,128.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Neena Patil sold 1,200 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the sale, the executive vice president directly owned 47,671 shares in the company, valued at approximately $11,485,850.74. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Up 0.0%

JAZZ traded up $0.07 during trading on Monday, reaching $245.87. The stock had a trading volume of 465,442 shares, compared to its average volume of 951,054. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $15.96 billion, a price-to-earnings ratio of 16.96, a P/E/G ratio of 0.22 and a beta of 0.36. The stock’s 50 day moving average is $249.37 and its two-hundred day moving average is $224.08. Jazz Pharmaceuticals PLC has a one year low of $123.88 and a one year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The business’s quarterly revenue was up 15.5% on a year-over-year basis. During the same quarter last year, the firm posted ($8.25) EPS. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 21.5 earnings per share for the current year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $25,000. Ameritas Advisory Services LLC purchased a new position in shares of Jazz Pharmaceuticals in the second quarter worth $47,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Jazz Pharmaceuticals in the second quarter worth $61,000. Westpac Banking Corp bought a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $51,000. Finally, Leonteq Securities AG bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $50,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $264.00 to $281.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. Royal Bank Of Canada set a $299.00 price objective on Jazz Pharmaceuticals in a research report on Friday, August 28th. Piper Sandler lifted their price objective on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. UBS Group boosted their target price on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a report on Friday. Finally, Needham & Company LLC raised their price target on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $286.72.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.